UBS Group
ADCT icon

UBS Group’s ADC Therapeutics ADCT Stock Holding History

UBS Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
458,902
+243,690
+113% +$961K ﹤0.01% 5102
2025
Q4 		$760K Sell
215,212
-47,049
-18% -$191K ﹤0.01% 5802
2025
Q3 		$1.05M Sell
262,261
-565,314
-68% -$1.78M ﹤0.01% 5536
2025
Q2 		$2.22M Buy
827,575
+60,511
+8% +$127K ﹤0.01% 4707
2025
Q1 		$1.08M Sell
767,064
-117,454
-13% -$200K ﹤0.01% 5225
2024
Q4 		$1.76M Buy
884,518
+844,743
+2,124% +$2.21M ﹤0.01% 4841
2024
Q3 		$125K Buy
39,775
+18,582
+88% +$58.6K ﹤0.01% 6199
2024
Q2 		$67K Buy
21,193
+21,142
+41,455% +$84K ﹤0.01% 6458
2024
Q1 		$229 Buy
+51
New +$188 ﹤0.01% 8707
2023
Q2 		– Sell
-11,302
Closed -$22K – 8824
2023
Q1 		$22K Buy
11,302
+8,386
+288% +$30.9K ﹤0.01% 7011
2022
Q4 		$11.2K Buy
+2,916
New +$11.7K ﹤0.01% 8430
2022
Q1 		– Sell
-2,426
Closed -$49K – 10169
2021
Q4 		$49K Buy
+2,426
New +$58.5K ﹤0.01% 6905
2021
Q3 		– Sell
-157
Closed -$4K – 9461
2021
Q2 		$4K Hold
157
– – ﹤0.01% 8647
2021
Q1 		$4K Sell
157
-1,308
-89% -$37.9K ﹤0.01% 8404
2020
Q4 		$47K Buy
1,465
+1,324
+939% +$43.4K ﹤0.01% 6236
2020
Q3 		$5K Buy
+141
New +$6.1K ﹤0.01% 7284

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group's ADCT Position: Q1 2026 in Review

UBS Group increased its ADC Therapeutics (ADCT) stake by 113% in Q1 2026, buying an estimated $961K and bringing the position to 458,902 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #5102.

UBS Group first reported a position in ADCT in Q3 2020 and has held it in 16 quarters since. The position peaked at $2.22M in Q2 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • UBS Group held 458,902 shares of ADC Therapeutics worth $1.72M as of Q1 2026.
  • UBS Group bought 243,690 ADC Therapeutics shares in Q1 2026, an estimated $961K.
  • ADC Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5102 holding.
  • UBS Group first reported a position in ADC Therapeutics in Q3 2020 and has held it in 16 quarters since.
  • UBS Group's ADC Therapeutics position peaked at $2.22M in Q2 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.